Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need.
In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft.
Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital.
The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.
Fields of science
Call for proposalSee other projects for this call